As a newcomer to the orthopaedic community, Ferring Pharmaceuticals Inc. will soon be introducing a new treatment option for knee osteoarthritis pain. The new product, expected to launch in October 2005, follows Ferring’s tradition of working with compounds that closely resemble those found naturally in the body. Since we look forward to working together in just a few short months, please take a few moments to familiarize yourself with the Company: Ferring Pharmaceuticals Inc. was established in the U.S. in 1981 as part of the Ferring Group, an international biopharmaceutical company founded in Sweden in 1951. The Ferring Group, privately owned with more than 2,500 employees worldwide, specializes in the research, development and commercialization of compounds and innovative products in the areas of obstetrics/gynecology, pediatric endocrinology, urology and gastroenterology. The Company has a local marketing presence in more than 40 countries with products in distribution in more than 70 countries. When Ferring Pharmaceuticals was established in 1981, its mission was to develop innovative compounds and license the marketing rights to other pharmaceutical companies, such as DDAVP for the treatment of bedwetting and Pentasa for the treatment of Crohn’s disease. By the end of the 1980s, the Company expanded its operation and began to market compounds under its own name with its own marketing force. Ferring’s success in specialty markets in the U.S. is underscored by its offerings in the infertility arena where the Company’s injectable fertility medications are now the most frequently prescribed in the U.S. Ferring provides effective, affordable treatment options that help patients create families. The U.S. operation, Ferring Pharmaceuticals Inc., is headquartered in This report provides an overview of how Ferring’s guiding principles propelled the Company to success in another therapeutic area - infertility. These same principles will guide Ferring in osteoarthritis.
Ferring entered the U.S. infertility market in 1997 with the first of its family of four infertility treatments. The Company developed a dedicated marketing and sales force and began to build relationships that would later make Ferring one of the most respected companies in the field, and the one with the most frequently prescribed gonadotropins (injectable hormones used by reproductive endocrinologists) – a milestone reached in late 2004. Ferring partnered with physicians, nurses and pharmacists to provide patients with safe, effective and affordable treatment options. The Company also invested in the patient, providing programs such as the H.E.A.R.T. Program (Helping Expand Access to Reproductive Therapy), a cost savings program, and the My Little Miracle Essay Contest, which provides $25,000 in education funds to children born with the help of Ferring’s treatments. These are major advances in the reproductive-endocrinology market.
Another key to Ferring’s success is its commitment to understanding the science of reproductive medicine and sharing its findings with the infertility community. This commitment has been underscored by extensive research – since 1997, Ferring has completed 26 gonadotropin clinical studies involving 3,760 patients. Ferring’s focus on research led to the product and patient benefits that the Company has brought to the market: the first subcutaneous human menopausal gonadotropin (hMG) – a more the first gonadotropin approved on the basis of pregnancy rates – setting the standard by which all subsequent gonadotropins will be evaluated for FDA approval; the first hMG with an enhanced purification process to ensure a high purity Ferring’s tradition is rich with strong relationships within the communities where it has treatment offerings. We look forward to building the same strong and lasting relationships with you and your peers. Working together, we can ensure that patients have access to safe and effective therapy for the treatment of knee osteoarthritis pain. For more information,


Microsoft word - r6199034.rtf

Safety Data Sheet Oxybutynin Hydrochloride Revision date : 2011/09/28 1. Product and Company Identification 2. Hazards Identification Emergency overview WARNING: HARMFUL IF SWALLOWED. May cause eye damage. Possible risk of harm to the unborn child. KEEP OUT OF REACH OF CHILDREN. INGESTION MAY CAUSE GASTRIC DISTURBANCES. CAN FORM EXPLOSIVE DUST-AIR MIXTURES. Avoid c


OKTOBER 2005 BC -., >/C 9-7>. 128D'20. 1/7.0*/5E 6 B/D-.2* *7-9 8/>D7FE ' B 2>D2>E 0->>/55>H-I>7 .-?29*71-H7 6 8/= />.->7" ' " ! 5.* ' ; -38-2 ,/+7*-7 L "<= -4*242>.*28/*H/: : J3-*>-40 ->?*29*7= 54/= H/J-40 E 6 B0*/D>-4 0*-H -4/8>E ' H038H7>7*/D>25. >/05?/,7 6 5/>-H7 /J/>K/4 ' />.H0* 57= 2J78 !54*-:>25.- =

Copyright © 2008-2018 All About Drugs